Recent News

Sixteen exceptional early-career scientists are advancing groundbreaking biomedical research at MSK thanks to the generous support of MSK philanthropists. These postdoctoral researchers, selected for their innovative research proposals and scientific promise, represent the future of oncology discovery. 

New MSK research shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; reveals tumor CD19 levels may predict the success of CAR T cell therapy; and finds a new targeted drug combination shows promise in early trial for small cell lung cancer.

How MSK researchers are using artificial intelligence (AI) to design better "binders" for CAR T cell therapies.

MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

The final paper from the lab of the late MSK Developmental Biology Chair Kathryn Anderson reveals how a critical signaling molecule called WNT guides cells in the embryo from a state of high flexibility — known as "plasticity" — toward distinct, specialized identities. Completing it was a labor of love for her colleagues.

A team of scientists from MSK and Weill Cornell Medicine found a small subset of T cells, called stem T cells, are responsible for making new T cells and for continuously replenishing them in chronic disease. The findings open the door to new treatment strategies for chronic conditions like cancer, autoimmune diseases, and infections.

New MSK research investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; uncovers Americans’ changing relationship with dietary supplements; and reveals how NK cells respond to infections so quickly.

MSK scientists are part of an international consortium working to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.

New MSK research decodes how mesothelioma evades immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source AI-driven drug discovery initiative.